StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Loan & DebtMay 14, 2026, 04:37 PM

Ocugen Closes $130M Convertible Notes Offering, Extends Cash Runway

AI Summary

Ocugen, Inc. announced the closing of its private offering of $130.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034, which includes the full exercise of a $15.0 million over-allotment option. The company expects approximately $112.6 million in net proceeds, using $32.7 million to repay an outstanding loan. This financing is anticipated to extend Ocugen's cash runway into 2028, supporting the advancement of three late-stage programs and the goal of filing three BLAs by 2028.

Key Highlights

  • Closed private offering of $130.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034.
  • Includes full exercise of $15.0 million over-allotment option.
  • Expected net proceeds of approximately $112.6 million after expenses.
  • Used $32.7 million of net proceeds to fully repay the Avenue Loan Agreement.
  • Anticipates extending cash runway into 2028.
  • Aims to advance three late-stage programs and file three BLAs by 2028.
  • Maximum of 8,108,108 shares of common stock may be issued upon conversion of additional notes.